Perspective Therapeutics, Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 2 insiders sold shares within a monthSince Sep 4, 2026+4.8
Trials
- CATXPerspective Therapeutics5Calm
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Signing up patientsPhase 1/2112 patientsMain results: Jan 31, 2028 - CATXPerspective Therapeutics5Calm
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Signing up patientsPhase 1/2300 patientsMain results: Nov 26, 2029 - CATXPerspective Therapeutics5Calm
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Signing up patientsPhase 1/2300 patientsMain results: Dec 31, 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
7 sales (7 not pre-planned) · 0 purchases
- Lantheus Alpha Therapy, LLCLarge shareholder · Sep 4, 2026Sold 167,149 sharesabout $526 thousand · not pre-planned
- Lantheus Alpha Therapy, LLCLarge shareholder · Sep 3, 2026Sold 80,783 sharesabout $251 thousand · not pre-planned
- Lantheus Alpha Therapy, LLCLarge shareholder · Sep 2, 2026Sold 42,129 sharesabout $131 thousand · not pre-planned
- Lantheus Alpha Therapy, LLCLarge shareholder · Sep 1, 2026Sold 35,769 sharesabout $112 thousand · not pre-planned
- Lantheus Holdings, Inc.Large shareholder · Sep 1, 2026Sold 35,769 sharesabout $112 thousand · not pre-planned
- Lantheus Alpha Therapy, LLC
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.